Abstract

Perilla frutescens (L.) Britton is a classic herbal plant used widely against asthma in China. But its mechanism of beneficial effect remains undermined. In the study, the antiallergic asthma effects of Perilla leaf extract (PLE) were investigated, and the underlying mechanism was also explored. Results showed that PLE treatment significantly attenuated airway inflammation in OVA-induced asthma mice, by ameliorating lung pathological changes, inhibiting recruitment of inflammatory cells in lung tissues and bronchoalveolar lavage fluid (BALF), decreasing the production of inflammatory cytokines in the BALF, and reducing the level of immunoglobulin in serum. PLE treatment suppressed inflammatory response in antigen-induced rat basophilic leukemia 2H3 (RBL-2H3) cells as well as in OVA-induced human peripheral blood mononuclear cells (PBMCs). Furthermore, PLE markedly inhibited the expression and phosphorylation of Syk, NF-κB, PKC, and cPLA2 both in vivo and in vitro. By cotreating with inhibitors (BAY61-3606, Rottlerin, BAY11-7082, and arachidonyl trifluoromethyl ketone) in vitro, results revealed that PLE's antiallergic inflammatory effects were associated with the inhibition of Syk and its downstream signals NF-κB, PKC, and cPLA2. Collectively, the present results suggested that PLE could attenuate allergic inflammation, and its mechanism might be partly mediated through inhibiting the Syk pathway.

Highlights

  • Asthma is one of the most common respiratory diseases characterized by varying degrees of chronic airway inflammation [1]

  • By using H&E staining (Figures 1(a) and 1(b)), the results of lung histologic changes showed that Perilla leaf extract (PLE) treatment markedly attenuated OVA-induced extensive accumulation of inflammatory cells into bronchi and vein regions in a dosedependent manner (P < 0:01)

  • In agreement with the histologic appearance, PLE treatment significantly decreased the number of total leukocytes, lymphocytes, monocytes, neutrophils, and eosinophils in bronchoalveolar lavage fluid (BALF) of asthma mice (P < 0:05 or 0.01, Figure 1(c))

Read more

Summary

Introduction

Asthma is one of the most common respiratory diseases characterized by varying degrees of chronic airway inflammation [1]. With increasing prevalence, it causes 250,000 deaths annually and will affect approximately 400 million individuals globally by 2025 [1, 2]. The most effective antiinflammatory drugs used in asthma are inhaled corticosteroids (ICS) to suppress airway inflammation [3]. The intake of ICS is associated with numerous adverse effects, including impaired growth in children, suppressed hypothalamic-pituitary axis, and increased risk of infections [6]. There is an urgent need to develop novel anti-inflammatory drugs for asthma treatment

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call